GL-S (Survodutide) 10mg

GL-S Molecule (SUVODUTIDE)

(Prescription Only – Free Consultation Required)

Dual-Receptor Therapy for Fat Loss, Appetite Control & Metabolic Optimization

Formulation

GL-S Core 10

1 × 10mg GL-S (Survodutide) Vial

Each vial contains:

• 10mg GL-S (Survodutide)
• Reconstituted with 4mL bacteriostatic water
• Total Volume: 4mL
• Concentration: 10mg / 4mL (2.5mg/mL)
• 100-unit insulin syringe dosing

Total Package Contents

• 10mg GL-S (Survodutide)

Classification

Prescription Only – Requires Provider Consultation & Approval

What Is GL-S Therapy?

GL-S (Survodutide) is a prescription dual-receptor metabolic therapy that simultaneously activates two key physiological pathways involved in appetite regulation, energy expenditure, fat metabolism, and metabolic health:

• GLP-1 (Glucagon-Like Peptide-1) Receptor
• Glucagon Receptor

Unlike traditional GLP-1 therapies that primarily reduce appetite, GL-S combines the established appetite-suppressing effects of GLP-1 receptor activation with glucagon receptor stimulation, increasing energy expenditure and encouraging the body to utilize stored fat as fuel.

Rather than relying solely on reduced calorie intake, GL-S addresses both sides of the metabolic equation by helping patients consume fewer calories while simultaneously increasing daily caloric expenditure. This complementary mechanism is designed to improve overall body composition rather than simply reducing body weight.

Early clinical studies have demonstrated substantial reductions in body weight along with encouraging improvements in liver fat content, insulin sensitivity, and markers of metabolic health.

Potential benefits may include:

• Significant appetite suppression
• Increased satiety
• Accelerated fat loss
• Increased daily calorie expenditure
• Enhanced fat oxidation
• Improved insulin sensitivity
• Reduction in visceral adiposity
• Improved metabolic flexibility
• Potential improvement in metabolic dysfunction-associated steatotic liver disease (MASLD)
• Long-term improvements in body composition

GL-S represents one of the newest generations of metabolic therapy designed for provider-directed weight management and comprehensive metabolic optimization.

All GL-S therapies require medical consultation and prescription approval before treatment begins.

Why Survodutide?

Among today's advanced metabolic therapies, Survodutide occupies a unique position.

While Tirzepatide combines GLP-1 and GIP receptor activation, and Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, Survodutide focuses exclusively on GLP-1 and glucagon receptor activation.

By removing GIP receptor activity and emphasizing glucagon-mediated energy expenditure, GL-S may provide an excellent option for patients seeking significant body fat reduction while promoting increased metabolic activity and fat oxidation.

Current evidence suggests Survodutide may produce weight-loss outcomes approaching those seen with Tirzepatide while offering unique metabolic effects that distinguish it from other incretin-based therapies.

Research-Based Mechanisms

🔥 Dual-Receptor Activation for Comprehensive Fat Loss

GL-S simultaneously activates both the GLP-1 and glucagon receptors, creating complementary metabolic effects that influence multiple aspects of energy balance.

GLP-1 receptor activation contributes to:

• Appetite suppression
• Increased satiety
• Delayed gastric emptying
• Reduced caloric intake
• Improved glucose regulation

Glucagon receptor activation contributes to:

• Increased energy expenditure
• Enhanced fat oxidation
• Greater utilization of stored fat
• Improved metabolic flexibility
• Potential preservation of resting metabolic rate during weight loss

Together, these mechanisms may provide a more comprehensive approach to body composition optimization than appetite suppression alone.

Potential benefits include:

• Reduced hunger
• Improved fullness
• Increased fat utilization
• Greater calorie expenditure
• Improved metabolic efficiency
• Better preservation of lean tissue during weight loss
• Enhanced body composition

Phase II clinical trials have demonstrated placebo-adjusted body-weight reductions approaching 15–19%, with continued improvements observed during longer treatment durations.

🩸 Improved Glycemic Control & Insulin Sensitivity

GL-S improves glucose regulation primarily through GLP-1 receptor activation while supporting healthier insulin responsiveness throughout treatment.

Potential benefits include:

• Improved insulin sensitivity
• Lower fasting glucose
• Reduced HbA1c
• Improved metabolic health
• Better nutrient partitioning
• Reduced insulin resistance

Clinical studies have consistently demonstrated meaningful improvements in glycemic control alongside substantial body-weight reduction.

🧠 Appetite Suppression & Craving Control

GL-S acts on appetite centers within the brain while slowing gastric emptying, helping patients naturally consume fewer calories without constant hunger.

Many patients report:

• Less frequent hunger
• Earlier fullness during meals
• Reduced food cravings
• Easier dietary adherence
• Improved long-term consistency

These effects frequently make sustained calorie reduction significantly easier than lifestyle intervention alone.

🧬 Increased Fat Oxidation & Energy Expenditure

One of the defining characteristics of Survodutide is glucagon receptor activation.

Unlike therapies that rely almost exclusively on appetite suppression, GL-S actively encourages increased energy expenditure while promoting utilization of stored fat.

Potential benefits include:

• Increased fat oxidation
• Higher daily calorie expenditure
• Improved metabolic flexibility
• Greater visceral fat reduction
• Improved body composition
• Potential reduction in adaptive metabolic slowing during weight loss

This dual mechanism represents one of the major advantages of GL-S therapy.

🫀 Potential Benefits for Liver Health

Survodutide has demonstrated encouraging early clinical results in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Clinical studies have shown reductions in liver fat content along with improvements in markers of metabolic health.

Potential benefits include:

• Reduced hepatic fat accumulation
• Improved liver enzyme profiles
• Reduced insulin resistance
• Improved metabolic function
• Support for overall cardiometabolic health

Research in this area continues to expand.

⚕ Clinical Access & Provider Oversight

GL-S therapy requires ongoing medical supervision.

Treatment includes:

• Initial provider consultation
• Prescription approval
• Individualized dosing plan
• Conservative dose escalation
• Regular follow-up
• Progress monitoring
• Body composition assessment
• Medication adjustments as needed

Recommended laboratory monitoring may include:

• HbA1c
• Fasting glucose
• Comprehensive Metabolic Panel (CMP)
• Lipid Panel
• Liver Function Tests (AST/ALT)

💉 Dosing Protocol (GL-S Core 10)

Dosing Equivalency

After reconstitution:

Standard Starting Protocol

GL-S utilizes the same conservative provider-directed titration philosophy used throughout our metabolic optimization program.

Because Survodutide activates both the GLP-1 and glucagon receptors, slower dose escalation often improves tolerability while maintaining excellent clinical outcomes.

Standard Initiation Schedule

Beginning in Week 3, patients generally continue increasing by approximately 1 unit per injection every 2–4 weeks as needed based upon:

• Appetite suppression
• Weight-loss progress
• Medication tolerance
• Gastrointestinal symptoms
• Provider assessment

Unlike fixed titration schedules, patients are encouraged to remain on the lowest effective dose while meaningful progress continues.

Dose Adjustment Guidelines

Remain on the current dose while:

• Weight continues decreasing
• Appetite remains well controlled
• Side effects remain minimal

Consider increasing by 1 unit per injection (2 units weekly) only if:

• Weight loss plateaus for two or more consecutive weeks
• Appetite suppression significantly decreases
• Medication continues to be well tolerated

If side effects occur:

• Reduce to the previous tolerated dose
• Remain there until symptoms resolve
• Resume gradual titration only under provider supervision

There is no requirement to reach the highest dose if therapeutic goals are being achieved.

Relative Clinical Comparison

Because these medications activate different receptor combinations, milligram doses cannot be directly converted. Instead, the table below provides a comparison of typical maintenance therapy and overall metabolic activity.

*Approximate results reported in Phase II/III clinical trials and may vary based on treatment duration, adherence, nutrition, exercise, and individual response.

Administration

Route: Subcutaneous Injection

Recommended Injection Sites

• Abdomen (preferred)
• Upper thigh
• Upper outer arm

Rotate injection sites regularly to minimize irritation and support consistent medication absorption.

For best consistency, administer GL-S on the same two days each week, approximately 3–4 days apart (for example, Monday and Thursday). While exact timing is not critical, maintaining a regular schedule helps establish routine and supports long-term adherence.

Ideal Use

GL-S Core 10 is intended for patients beginning therapy with a next-generation dual-receptor metabolic medication under provider supervision.

By combining GLP-1 receptor activation with glucagon receptor stimulation, GL-S addresses multiple aspects of metabolic health simultaneously. Rather than relying exclusively on appetite suppression, it also encourages increased energy expenditure and utilization of stored fat, providing a unique approach to improving body composition.

GL-S may be an excellent option for individuals seeking:

• Sustainable fat loss
• Improved appetite control
• Enhanced metabolic flexibility
• Better insulin sensitivity
• Reduction in visceral adiposity
• Improvements in fatty liver disease (MASLD)
• Long-term metabolic optimization

Every treatment plan is individualized based on body composition goals, medical history, laboratory findings, medication tolerance, and overall clinical response.

Approximate Treatment Duration

Treatment duration varies based on individualized dosing. Because GL-S follows a gradual, provider-directed titration schedule, patients often remain on lower doses for extended periods while continuing to achieve meaningful progress.

The estimates below assume a 10mg vial reconstituted with 4mL bacteriostatic water (2.5mg/mL).

Actual treatment duration will vary depending on dose adjustments, treatment response, and provider recommendations.

Typical Program Length

GL-S is commonly incorporated into a 3–12 month provider-guided metabolic optimization program, with comprehensive reassessment every 8–12 weeks.

These follow-up evaluations may include:

• Body weight
• Body composition analysis
• Waist circumference
• Appetite assessment
• Medication tolerance
• Laboratory review
• Dose optimization
• Nutrition review
• Exercise progression
• Long-term maintenance planning

The objective is not simply rapid weight loss, but sustainable improvements in overall metabolic health while preserving lean body mass and supporting long-term success.

Compatible Therapy Stacks

KPV

KPV supports gastrointestinal health, intestinal barrier integrity, and inflammatory balance, making it an excellent adjunct during GL-S therapy, particularly for patients experiencing gastrointestinal sensitivity during dose escalation.

Potential benefits include:

• Improved gut health
• Support for intestinal barrier function
• Reduction in gastrointestinal inflammation
• Enhanced digestive comfort

Tesamorelin

Tesamorelin complements GL-S by supporting lean muscle preservation while promoting preferential reduction of visceral adipose tissue.

Potential benefits include:

• Preservation of lean body mass
• Visceral fat reduction
• Improved body composition
• Support for healthy growth hormone physiology

MOTS-C

MOTS-C supports mitochondrial function and cellular energy metabolism, complementing the metabolic improvements produced by GL-S.

Potential benefits include:

• Improved insulin sensitivity
• Enhanced metabolic flexibility
• Increased cellular energy production
• Exercise performance support
• Improved glucose utilization

GHK-Cu

GHK-Cu supports regenerative health during weight loss by promoting tissue repair, collagen synthesis, and healthy recovery.

Potential benefits include:

• Tissue repair
• Skin quality support
• Collagen production
• Recovery optimization
• Healthy aging support

Why Our Approach Is Different

Successful long-term weight management involves far more than simply prescribing medication.

Every GL-S treatment plan is designed around a comprehensive metabolic optimization strategy that emphasizes:

• Individualized provider oversight
• Conservative dose titration
• Nutrition coaching
• Resistance training
• Lean muscle preservation
• Routine laboratory monitoring
• Body composition analysis
• Long-term maintenance planning

Our goal is to improve overall health—not simply reduce the number on the scale.

📦 Every Order Includes

• 1 × 10mg GL-S (Survodutide) vial
• Sterile bacteriostatic water (when applicable)
• Insulin syringes
• Alcohol swabs
• Sharps disposal bag
• Printed dosing guide
• Reconstitution instructions
• Injection guide
• Storage instructions
• Ongoing provider support throughout treatment
• Follow-up dosing recommendations as needed

📧 Questions?

ProPeptides

Email: Admin@ProPeptides.com

Phone: (480) 400-6225

🛡️ Dual-Receptor Precision. Advanced Metabolic Therapy. Clinical Oversight.

GL-S Core 10 combines the appetite-regulating effects of GLP-1 receptor activation with the energy-expending benefits of glucagon receptor stimulation, providing a unique dual-mechanism approach to metabolic optimization.

By simultaneously reducing caloric intake while encouraging greater utilization of stored fat, GL-S supports meaningful improvements in body composition, insulin sensitivity, metabolic flexibility, and overall metabolic health.

Unlike traditional weight-loss medications that focus primarily on appetite suppression, GL-S is designed to influence multiple physiological pathways involved in energy balance. This comprehensive approach may help patients achieve substantial and sustainable reductions in body fat while supporting healthier long-term metabolic function.

Every treatment plan is customized by a licensed provider and combined with structured nutrition, resistance training, routine laboratory monitoring, and regular follow-up visits to maximize results while maintaining safety and tolerability.

When integrated into a comprehensive lifestyle program, GL-S offers one of the most promising emerging approaches to provider-guided metabolic optimization and long-term body composition improvement.

Selected References

Tillner J, et al. Effects of survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, in adults with overweight or obesity: Phase II clinical trial.

Boehringer Ingelheim & Zealand Pharma. SYNCHRONIZE™ Clinical Development Program evaluating Survodutide for obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiometabolic disease.

Loomba R, et al. Phase II clinical evaluation of Survodutide in metabolic dysfunction-associated steatohepatitis (MASH), demonstrating improvements in liver fat content and metabolic biomarkers.

Jastreboff AM, et al. Advances in incretin-based therapies for obesity and metabolic disease. New England Journal of Medicine.

American Diabetes Association. Standards of Care in Diabetes—Pharmacologic Approaches to Glycemic Treatment.

Clinical Disclaimer

GL-S (Survodutide) is available only through licensed healthcare providers following medical consultation and prescription approval. Individual results vary based on age, underlying medical conditions, nutrition, physical activity, adherence to therapy, and numerous other factors. Treatment should always be combined with appropriate dietary modification, regular resistance exercise, and ongoing medical supervision. Survodutide remains under active clinical investigation for several indications, and recommendations should always follow current evidence, prescribing guidance, and provider judgment.